ROLUFTA

This brand name is authorized in Austria, Estonia, Spain, France, Croatia, Ireland, Italy, Lithuania, Poland, United Kingdom

Active ingredients

The drug ROLUFTA contains one active pharmaceutical ingredient (API):

1 Umeclidinium UNII GE2T1418SV - UMECLIDINIUM

Umeclidinium is a long acting muscarinic receptor antagonist (also referred to as an anticholinergic). It is a quinuclidine derivative that is a muscarinic receptor antagonist with activity across multiple muscarinic cholinergic receptor subtypes. Umeclidinium bromide exerts its bronchodilatory activity by competitively inhibiting the binding of acetylcholine with muscarinic cholinergic receptors on airway smooth muscle. Read about Umeclidinium

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
R03BB07		R Respiratory system → R03 Drugs for obstructive airway diseases → R03B Other drugs for obstructive airway diseases, inhalants → R03BB Anticholinergics
Discover more medicines within R03BB07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1742071, 1742082, 1742093
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1171174002
Country: FR	Base de données publique des médicaments	Identifier(s): 67728692
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 391678
Country: IT	Agenzia del Farmaco	Identifier(s): 045321015, 045321027, 045321039
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1082483, 1082484, 1082485
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100387119